| Literature DB >> 28372509 |
Rosa Bosch1,2, Alba Mora1,2, Eva Puy Vicente1,2, Gerardo Ferrer3, Sonia Jansà4, Rajendra Damle3, Sergey Gorlatov5, Kanti Rai6, Emili Montserrat7, Josep Nomdedeu8, Marta Pratcorona8, Laura Blanco8, Silvana Saavedra2, Ana Garrido2, Albert Esquirol2, Irene Garcia2, Miquel Granell2, Rodrigo Martino2, Julio Delgado7, Jorge Sierra1,2, Nicholas Chiorazzi3, Carol Moreno1,2.
Abstract
In normal B-cells, B-cell antigen receptor (BCR) signaling can be negatively regulated by the low-affinity receptor FcγRIIb (CD32b). To better understand the role of FcγRIIb in chronic lymphocytic leukemia (CLL), we correlated its expression on 155 samples from newly-diagnosed Binet A patients with clinical characteristics and outcome. FcγRIIb expression was similar in normal B-cells and leukemic cells, this being heterogenous among patients and within CLL clones. FcγRIIb expression did not correlate with well known prognostic markers [disease stage, serum beta-2 microglobulin (B2M), IGHV mutational status, expression of ZAP-70 and CD38, and cytogenetics] except for a weak concordance with CD49d. Moreover, patients with low FcγRIIb expression (69/155, 44.5%) required therapy earlier than those with high FcγRIIb expression (86/155, 55.5%) (median 151.4 months vs. not reached; p=.071). These results encourage further investigation on the role of FcγRIIb in CLL biology and prognostic significance in larger series of patients.Entities:
Keywords: B-cell activation; B-cell receptor; Chronic lymphocytic leukemia; FcγRIIb; treatment-free survival
Mesh：
Substances：
Year: 2017 PMID： 28372509 PMCID： PMC5526713 DOI： 10.1080/10428194.2017.1307981
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022